May 16, 2018 / 5:04 AM / 2 months ago

BRIEF-Idorsia Starts Phase 3 Registration Study To Assess Lucerastat As Potential New Treatment Option For Patients With Fabry Disease

May 16 (Reuters) - IDORSIA LTD:

* IDORSIA INITIATES MODIFY, A PHASE 3 REGISTRATION STUDY TO ASSESS LUCERASTAT AS A POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WITH FABRY DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below